Abstract
Purpose: No tumor marker has been shown to be useful in screening for pancreatic cancer. CA 19–9 is a widely used serological marker for pancreatic cancer, however, its role in screening and establishing the diagnosis of early stage disease is limited. Recently, syndecan-1 has been shown to be overexpressed early in pancreatic carcinogenesis. This transmembrane heparan sulfate-bearing proteoglycan can regulate adhesion, migration, and growth factor activity, processes critical to the early metastatic potential of pancreatic cancer. Syndecan-1 is frequently shed into the blood from malignant tissues. Indeed, serological assessment of this cell surface proteoglycan has been shown to be a useful marker in the diagnosis/prognosis in lung cancer and myeloma. Therefore, we hypothesized that serum syndecan-1 levels would be an accurate marker for pancreatic cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
